➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
AstraZeneca
Baxter
Dow
Mallinckrodt

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Centanafadine


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Centanafadine?

Centanafadine is an investigational drug.

There have been 8 clinical trials for Centanafadine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2018.

The most common disease conditions in clinical trials are Hyperkinesis, Attention Deficit Disorder with Hyperactivity, and Disease. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., Neurovance, Inc., and [disabled in preview].

There are fifteen US patents protecting this investigational drug and seventy-nine international patents.

Recent Clinical Trials for Centanafadine
TitleSponsorPhase
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity DisorderOtsuka Pharmaceutical Development & Commercialization, Inc.Phase 1
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity DisorderOtsuka Pharmaceutical Development & Commercialization, Inc.Phase 1
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Subjects With Attention-deficit Hyperactivity DisorderOtsuka Pharmaceutical Development & Commercialization, Inc.Phase 2

See all Centanafadine clinical trials

Clinical Trial Summary for Centanafadine

Top disease conditions for Centanafadine
Top clinical trial sponsors for Centanafadine

See all Centanafadine clinical trials

US Patents for Centanafadine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Centanafadine   Get Started Free 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders OTSUKA AMERICA PHARMACEUTICAL, INC. (Rockville, MD)   Get Started Free
Centanafadine   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Centanafadine   Get Started Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Johnson and Johnson
Mallinckrodt
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.